Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Stacy Hu, Steven B Koevary

Abstract

The purpose of this study was to determine whether nonspecific and ICAM-1-specific IgG1 antibodies can accumulate in the rat retina following topical application, and to develop a model system to show that antibodies that reach the posterior segment retain their pharmacological properties. Eye drops containing mouse IgG1 or anti-ICAM-1 and the permeation enhancer saponin were topically applied to the eyes of Lewis rats. Concentrations were determined in the retina and optic nerve up to 30 min later using ELISA assays. We also developed an in vitro model to assess the pharmacologic activity of topically delivered antibodies in the retina based on the requirement of human umbilical vein endothelial cells (HUVECs) for vascular endothelial growth factor (VEGF) for growth. Rat eyes were treated with anti-VEGF antibody in the same manner as above; their retinas, harvested shortly thereafter, were added to HUVECs cultured in VEGF-containing media. The effect of these retinal homogenates on HUVEC proliferation was then assessed. Significant concentrations of IgG1 were detected in the optic nerve (P < 0.001) and retina (P < 0.0001) following topical application. Anti-ICAM-1 antibody also accumulated in the retina after topical applicati...Continue Reading

References

May 1, 1985·Experimental Eye Research·M F MarmorD M Maurice
Aug 1, 1995·Clinical Pharmacokinetics·J P Frangie
Sep 15, 1999·Proceedings of the National Academy of Sciences of the United States of America·K MiyamotoA P Adamis
Sep 11, 2003·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Steven B KoevaryStephen Lake
Apr 3, 2004·Optometry : Journal of the American Optometric Association·Steven B KoevaryGeorgia Patsiopoulos
Oct 20, 2004·Retina·Rama D JagerEmmett T Cunningham
Jul 4, 2006·American Journal of Ophthalmology·Rishi P Singh, Jonathan E Sears
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Mar 28, 2009·Investigative Ophthalmology & Visual Science·Hiroyuki NomotoTetsuya Baba
Feb 16, 2010·Pharmaceutical Research·Esther Eljarrat-BinstockAbraham J Domb
Aug 13, 2010·Developments in Ophthalmology·Baruch D Kuppermann, Anat Loewenstein
Dec 21, 2010·Drug Discovery Today·Thilini Rasika ThrimawithanaRaid Ghassan Alany
Feb 25, 2011·The New England Journal of Medicine·Deborah A Martin, Sanjaya Senanayake
Apr 19, 2012·Current Eye Research·Mutasem Rawas-Qalaji, Cheryl-Ann Williams
May 11, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Philipp S MuetherSascha Fauser
Jan 31, 2014·Recent Patents on Drug Delivery & Formulation·Sai H S BodduSoohi Patel

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
Protein Assay
Assay

Software Mentioned

JMP
SigmaPlot
SAS
Statistical
Excel

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Biological & Pharmaceutical Bulletin
Do-Young ChoiDong-Suk Park
Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
Kun LuoHuiqi Xie
© 2022 Meta ULC. All rights reserved